New data on Probi Defendum confirms probiotics supporting the immune system
In one of the largest immune studies, Probi Defendum® confirms beneficial effect in supporting the immune system in fighting viral common colds.
While many people are trying to reduce their exposure towards bacteria and viruses these days, it is important to stress that many microbes are essential for good health – and some of these are probiotics with proven health effects.
Recently additional clinical validation has been published on Probi Defendum, this time in one of the largest immune health studies ever performed on probiotics. The randomized, double-blind, placebo-controlled multicenter study included 900 adults and confirmed the strong clinical immune health support of Probi Defendum.
“Almost 900 healthy adults - over three winter seasons - took part in the study, and the participants in the probiotic group experienced significantly fewer common cold episodes, compared to the placebo group, and fewer recurring colds. Probi Defendum is now supported by 4 clinical studies, which repeatedly have shown a beneficial effect”, explains Titti Niskanen, Director R&D & Clinical Operations. “And in addition, the study provided new data to support the hypothesized mechanism of action, i.e readying the immune system and supporting a complementary inflammatory response”, Niskanen continues.
Tom Rönnlund, CEO at Probi, emphasizes the importance of immune health: “We all know the benefits of a strong and healthy immune system, which has been particularly important this year.” He continues: “On average adults suffer from 2-4 episodes of common cold and upper respiratory tract infections per year and children as many as 6-8 yearly episodes, which results in many sick days and absence from daycare and workplaces. With these new data we again show that Probi Defendum can safely be used to support a healthy immune system and its ability to fight the common cold”.
The clinical trial, published in The Journal of Nutrition can be found [http://Fewer Community-Acquired Colds with Daily Consumption of Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus paracasei 8700:2. A Randomized, Placebo-Controlled Clinical Trial | The Journal of Nutrition | Oxford Academic (oup.com)]here.
For further information, please contact:
Titti Niskanen, Director R&D & Clinical Operations, Probi®,
Phone: +46 46 286 89 68, E-mail: titti.niskanen@probi.com
Tom Rönnlund, CEO, Probi®,
Phone: +46 46 286 89 40, E-mail: trd@probi.com
Charlotte Beyerholm, Director Marketing & Global Communication, Probi®,
Phone: +46 76 870 94 65, E-mail: charlotte.beyerholm@probi.com